The GRAPH-CRAFITY Score: a novel prognostic tool for patients with hepatocellular carcinoma treated with targeted therapy and immunotherapy

Motivation: Biomarkers that predict the efficacy of immunotherapy-based systematic therapy remain an unmet need in HCC. Goal(s): To establish an optimized model by integrating magnetic resonance (MR) features and CRAFITY score to predict overall survival (OS) of HCC patients treated with targeted therapy and immunotherapy. Approach: The clinical variables and MR features were assessed by univariate and multivariate Cox regression analyses. Results: Based on independent risk factors (Gender, intRatumoral fAt, enhancing tumor caPsule, gross growtH type and CRAFITY Score) identified by the multivariate analysis, a novel prognostic tool named GRAPH-CRAFITY Score was developed to predict OS. Impact: A novel prognostic tool by integrating gender, MR features and laboratory tests was developed to predict OS of HCC patients treated with targeted therapy and immunotherapy, which will help oncologists for decision-making.